home / stock / sprb / sprb quote
Last: | $0.5252 |
---|---|
Change Percent: | 0.97% |
Open: | $0.52 |
Close: | $0.5252 |
High: | $0.5338 |
Low: | $0.5104 |
Volume: | 475,312 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.5252 | $0.52 | $0.5252 | $0.5338 | $0.5104 | 475,312 | 07-22-2024 |
$0.5251 | $0.541 | $0.5251 | $0.5499 | $0.524 | 299,662 | 07-19-2024 |
$0.546 | $0.5574 | $0.546 | $0.5599 | $0.542 | 464,249 | 07-18-2024 |
$0.5621 | $0.5949 | $0.5621 | $0.5949 | $0.547 | 856,955 | 07-17-2024 |
$0.59 | $0.5836 | $0.59 | $0.5974 | $0.5836 | 531,102 | 07-16-2024 |
$0.5798 | $0.5699 | $0.5798 | $0.5949 | $0.5699 | 322,352 | 07-15-2024 |
$0.5749 | $0.5656 | $0.5749 | $0.578 | $0.5656 | 370,833 | 07-12-2024 |
$0.5674 | $0.5433 | $0.5674 | $0.57 | $0.5433 | 613,313 | 07-11-2024 |
$0.5474 | $0.5654 | $0.5474 | $0.5711 | $0.5314 | 688,802 | 07-10-2024 |
$0.564 | $0.5661 | $0.564 | $0.5824 | $0.5613 | 224,093 | 07-09-2024 |
$0.5697 | $0.5759 | $0.5697 | $0.5759 | $0.5651 | 82,707 | 07-08-2024 |
$0.5717 | $0.5631 | $0.5717 | $0.5824 | $0.5571 | 286,543 | 07-05-2024 |
$0.565 | $0.5273 | $0.565 | $0.565 | $0.5273 | 327,762 | 07-04-2024 |
$0.565 | $0.5273 | $0.565 | $0.565 | $0.5273 | 327,762 | 07-03-2024 |
$0.5273 | $0.5324 | $0.5273 | $0.5329 | $0.5151 | 263,730 | 07-02-2024 |
$0.5309 | $0.5201 | $0.5309 | $0.5379 | $0.5201 | 556,873 | 07-01-2024 |
$0.5177 | $0.5301 | $0.5177 | $0.5424 | $0.5176 | 537,917 | 06-28-2024 |
$0.5322 | $0.545 | $0.5322 | $0.5508 | $0.5252 | 515,666 | 06-27-2024 |
$0.5508 | $0.5699 | $0.5508 | $0.5724 | $0.55 | 309,547 | 06-26-2024 |
$0.56 | $0.557 | $0.56 | $0.5724 | $0.5411 | 377,396 | 06-25-2024 |
News, Short Squeeze, Breakout and More Instantly...
Spruce Biosciences Inc. Company Name:
SPRB Stock Symbol:
NASDAQ Market:
Spruce Biosciences Inc. Website:
Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, announced that the San Francisco Business Times and the Silicon Valley Busines...
Pairs Spruce’s Investigational Product Candidate, Tildacerfont, with HMNC’s Companion Diagnostic, the Proprietary Cortibon Genetic Selection Tool, to Treat MDD Patients Responsive to CRF 1 Receptor Antagonism Provides Spruce with Option to In-License Exclusive Worldwide ...
Significant Reduction in Dehydroepiandrosterone Sulfate ( DHEAS) Versus Placebo Observed in Women with Elevated DHEAS Levels at Baseline Increase in Serum Sex Hormone Binding Globulin (SHBG) Versus Placebo Observed Tildacerfont was Well-Tolerated with No Safety Signals ...